Project Grant R21AI196828
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $438,500 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 8, 2025, with a completion date of June 30, 2027. This award funds investigator-initiated biomedical research examining the sequence-specific determinants and impacts of NS2 (nonstructural protein 2) interactions with the Influenza A Virus...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $787,837 to The Regents of the University of California, San Francisco on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and apply computational tools for assessing disease transmission risk. The project, which extends through March 31, 2031, focuses on advancing analytical methods to quantify and mitigate the risk of infectious...
- Federal Grant Award Summary The University of California, San Diego received a $439,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 4, 2026, through January 31, 2028. This research project focuses on the discovery and characterization of mammalian serpins (serine protease inhibitors) as host-encoded viral protease inhibitors. The research will investigate...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $3.19 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of June 30, 2029. This grant funds investigator-initiated biomedical research examining the roles and regulation of tissue-resident CD8 T cells during persistent viral infection, utilizing the lymphocytic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2.83 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Irvine for the period of July 14, 2025 through June 30, 2029. The research investigates metabolic regulation by serine/threonine-protein phosphatase 6 regulatory subunit 3 (SAPS3) in virus-specific T cell immunity, with the objective of identifying novel...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Regents of the University of California, San Francisco $150,104 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on January 12, 2026, for a two-year project period concluding January 11, 2028. This Project Grant supports investigator-initiated biomedical research addressing infectious diseases through fundamental scientific inquiry and methodological...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $3,082,513 to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 18, 2025, for a four-year project period extending through June 30, 2029. The award supports research focused on optimizing lipid prodrug delivery formulations of remdesivir nucleoside monophosphate (RVN-MP) and related broad-spectrum nucleoside antivirals to...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Research Foundation for the State University of New York (RF SUNY) a Project Grant of $437,895 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 14, 2025, with a completion date of June 30, 2027. The grant supports research to elucidate the mechanistic role of galectin-3-binding protein (LGALS3BP/90K) during severe acute respiratory syndrome coronavirus...
- Federal Project Grant Award Summary The University of California, San Diego received a $438,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 8, 2025, through June 30, 2027. The award supports basic immunological research focused on understanding the mechanisms that regulate immunoglobulin gene rearrangement, specifically investigating how enhancers and epigenetic...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $815,762 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of February 19, 2026, and completion date of January 31, 2031. This research project will develop a quantitative understanding of how biophysical properties of antibodies impact their capacity to evolve affinity to...
Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $213,048 to the Regents of the University of California at Riverside under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. The research initiative, titled "N Protein Nexus: Rewiring Host Translation Machinery for SARS-CoV-2's Early Replicative Advantage," focuses on elucidating the molecular mechanisms by which the viral nucleocapsid (N) protein manipulates human translation machinery to establish a translational advantage during early SARS-CoV-2 infection. The research deliverables encompass fundamental scientific investigation and analysis across two primary objectives: (1) identifying viral determinants responsible for N protein's impact on viral RNA translation, and (2) delineating the roles of host factors in N protein-mediated viral translation enhancement. The project employs integrated biochemical, biophysical, and genetic approaches to establish a comprehensive understanding of host-virus interactions, with the ultimate goal of advancing knowledge regarding early-stage coronavirus replication mechanisms that may inform future therapeutic interventions and pandemic preparedness strategies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $213.0k | 4/1/26 |